2. ВОЗ. Глобальная стратегия сектора здравоохранения по вирусным гепатитам на 2016–2021 гг. http://apps.who.int/iris/bitstream/ 10665/246177/1/WHO-HIV-2016.06-eng.pdf

[World Health Organization. Global health sector strategy on viral hepatitis 2016–2021]. (In Russ.). http://apps.who.int/iris/bitstream/10665/246177/1/ WHO-HIV-2016.06-eng.pdf

3. Polaris Observatory HCV Collaborators. Global change in hepatitis C virus prevalence and cascade of care between 2015 and 2020: a modelling study. Lancet Gastroenterol. Hepatol. 2022; 7(5): 396–415. DOI: 10.1016/S2468-1253(21)00472-6

4. О состоянии санитарно-эпидемиологического благополучия населения в Российской Федерации в 2022 году: Государственный доклад. М.: Федеральная служба по надзору в сфере защиты прав потребителей и благополучия человека, 2023. 368 с.

[On the state of sanitary and epidemiological well-being of the population in the Russian Federation in 2022: State report]. Moscow, 2023. 368 p. (In Russ.).

5. Abu-Dayyeh I., Chemaitelly H., Ghunaim M., Hasan T., Abdelnour A., Abu-Raddad L.J. Patterns and trends of hepatitis C virus infection in Jordan: an observational study. Front. Public Health 2023; 11: 1280427. DOI: 10.3389/fpubh.2023.1280427

6. Макашова В.В., Омарова Х.Г., Понежева Ж.Б., Ивашкова Т.А., Горелов А.В. Хронический гепатит С и его исходы: цирроз печени, гепатоцеллюлярная карцинома. Эпидемиол. инфекц. болезни. Актуал. вопр. 2023; 13(1): 99–104. DOI: 10.18565/epidem.2023. 13.1.99-104

Makashova V.V., Omarova Kh.G., Ponezheva Zh.B., Ivashkova T.A., Gorelov A.V. [Chronic hepatitis C and its outcomes: liver cirrhosis, hepatocellular carcinoma]. Epidemiоlоgy and infectious diseases. Сurrent items 2023. 13(1): 99–104. (In Russ.). DOI: 10.18565/epidem.2023.13.1.99-104

7. Kang J.G., Jang M.K., Kim J.H., Jung J.H., Park J.W., Kim S.E. et al. The diagnostic significance of hepatitis C virus antibody levels for chronic hepatitis C virus infection. Korean J. Intern. Med. 2023; 38(3): 362–71. DOI: 10.3904/kjim.2022.350

8. ВОЗ. Глобальный доклад о ходе борьбы с ВИЧ, вирусными гепатитами и инфекциями, передаваемыми половым путем, 2021 год. https://www.who.int/publications/i/item/9789240027077

[World Health Organization. Global Progress Report on HIV, Viral Hepatitis and Sexually Transmitted Infections, 2021]. (In Russ.). https://www.who.int/ publications/i/ item/9789240027077

9. Маев И.В., Кузнецова Е.И., Андреев Д.Н., Дичева Д.Т. Диагностическая точность предиктивных индексов оценки фиброза печени у пациентов с хроническим гепатитом С. Терапевтический архив 2020; 92(2): 24–8. DOI: 10.26442/00403660.2020.02.000261

Maev I.V., Kuznetsova E.I., Andreev D.N., Dicheva D.T. Diagnostic accuracy of predictive indexes of liver fibrosis in patients with chronic hepatitis C. Therapeutic Archive 2020; 92(2): 24–8. (In Russ.). DOI: 10.26442/00403660.2020.02.000261

10. Midia M., Odedra D., Shuster A., Midia R., Muir J. Predictors of bleeding complications following percutaneous image-guided liver biopsy: a scoping review. Diagn. Interv. Radiol. 2019; 25(1): 71–80. DOI: 10.5152/dir.2018.17525

11. Colling R., Verrill C., Fryer E., Wang L.M., Fleming K. Discrepancy rates in liver biopsy reporting. J. Clin. Pathol. 2014; 67(9): 825–7. DOI: 10.1136/jclinpath-2014-202261

12. Parikh N.D., Mehta M., Tapper E.B. FIB-4 and APRI for cirrhosis detection in a privately insured national cohort. JHEP Rep. 2023; 6(1): 100925. DOI: 10.1016/j.jhepr.2023.100925

13. Lai J.C., Liang L.Y., Wong G.L. Noninvasive tests for liver fibrosis in 2024: are there different scales for different diseases? Gastroenterol. Rep. (Oxf.). 2024; 12: goae024. DOI: 10.1093/gastro/goae024

14. Laursen T.L., Sandahl T.D., Kazankov K., George J., Grønbæk H. Liver-related effects of chronic hepatitis C antiviral treatment. World J Gastroenterol. 2020; 26(22): 2931–47. DOI: 10.3748/wjg.v26.i22.2931

15. Tang Z., Xia Z., Wang X., Liu Y. The critical role of osteopontin (OPN) in fibrotic diseases. Cytokine Growth Factor Rev. 2023; 74: 86–99. DOI: 10.1016/j.cytogfr.2023.08.007

16. Bruha R., Vitek L., Smid V. Osteopontin – A potential biomarker of advanced liver disease. Ann Hepatol. 2020; 19(4): 344–352. DOI: 10.1016/j.aohep.2020.01.001

17. Briones-Orta M.A. Avendaño-Vázquez S.E., Aparicio-Bautista D.I., Coombes J.D., Weber G.F., Syn W.K. Osteopontin splice variants and polymorphisms in cancer progression and prognosis. Biochim. Biophys. Acta Rev. Cancer 2017; 1868(1): 93–108A. DOI: 10.1016/j.bbcan.2017.02.005

18. Lamort A.S., Giopanou I., Psallidas I., Stathopoulos G.T. Osteopontin as a Link between Inflammation and Cancer: The Thorax in the Spotlight. Cells 2019; 8(8): 815. DOI: 10.3390/cells8080815

19. Lok Z.S.Y., Lyle A.N. Osteopontin in Vascular Disease. Arterioscler. Thromb. Vasc. Biol. 2019; 39(4): 613–22. DOI: 10.1161/ATVBAHA. 118.311577.

20. Yan Z., Hu X., Tang B., Deng F. Role of osteopontin in cancer development and treatment. Heliyon. 2023; 9(10):e21055. DOI: 10.1016/j.heliyon.2023.e21055

21. Bandopadhyay M., Bulbule A., Butti R., Chakraborty G., Ghorpade P., Ghosh P. et al. Osteopontin as a therapeutic target for cancer. Expert Opin. Ther. Targets. 2014; 18(8): 883–95. DOI: 10.1517/14728222.2014.925447

22. Maeda N., Maenaka K. The Roles of Matricellular Proteins in Oncogenic Virus-Induced Cancers and Their Potential Utilities as Therapeutic Targets. Int. J. Mol. Sci. 2017; 18(10): 2198. DOI: 10.3390/ijms18102198

23. Desert R., Ge X., Song Z., Han H., Lantvit D., Chen W. et al. Role of Hepatocyte-Derived Osteopontin in Liver Carcinogenesis. Hepatol. Commun. 2022; 6(4): 692–709. DOI: 10.1002/hep4.1845

24. Wen Y., Jeong S., Xia Q., Kong X. Role of Osteopontin in Liver Diseases. Int. J. Biol. Sci. 2016; 12(9): 1121–8. DOI: 10.7150/ijbs.16445

25. Huang W., Zhu G., Huang M., Lou G., Liu Y., Wang S. Plasma osteopontin concentration correlates with the severity of hepatic fibrosis and inflammation in HCV-infected subjects. Clin. Chim. Acta. 2010; 411(9–10): 675–8. DOI: 10.1016/j.cca.2010.01.029

26. Urtasun R., Lopategi A., George J., Leung T.M., Lu Y., Wang X. et al. Osteopontin, an oxidant stress sensitive cytokine, up-regulates collagen-I via integrin α(V)β(3) engagement and PI3K/pAkt/NFκB signaling. Hepatology 2012; 55(2): 594–608. DOI: 10.1002/hep.24701

27. Xiao X., Gang Y., Gu Y., Zhao L., Chu J., Zhou J. et al. Osteopontin contributes to TGF-β1 mediated hepatic stellate cell activation. Dig. Dis. Sci. 2012; 57(11): 2883–91. DOI: 10.1007/s10620-012-2248-7

28. Matsue Y., Tsutsumi M., Hayashi N., Saito T., Tsuchishima M., Toshikuni N. et al. Serum osteopontin predicts degree of hepatic fibrosis and serves as a biomarker in patients with hepatitis C virus infection. PLoS One 2015; 10(3): e0118744. DOI: 10.1371/journal.pone.0118744

29. Fouad S.A., Mohamed N.A., Fawzy M.W., Moustafa D.A. Plasma Osteopontin Level in Chronic Liver Disease and Hepatocellular Carcinoma. Hepat. Mon. 2015; 15(9) :e30753. DOI: 10.5812/hepatmon.30753

30. Arriazu E., Ge X., Leung T.M., Magdaleno F., Lopategi A., Lu Y. et al. Signalling via the osteopontin and high mobility group box-1 axis drives the fibrogenic response to liver injury. Gut. 2017 66(6) :1123–37. DOI: 10.1136/gutjnl-2015-310752

31. Sobhy A., Fakhry M. M., A Azeem H.., Ashmawy A.M., Omar Khalifa H. Significance of biglycan and osteopontin as non-invasive markers of liver fibrosis in patients with chronic hepatitis B virus and chronic hepatitis C virus. J. Investig. Med. 2019; 67(3): 681–5. DOI: 10.1136/jim-2018-000840

32. Leung T.M., Wang X., Kitamura N., Fiel M.I., Nieto N. Osteopontin delays resolution of liver fibrosis. Lab. Invest. 2013; 93(10): 1082–9. DOI: 10.1038/labinvest.2013.104

33. Tang M., Guo C., Sun M.., Zhou H, Peng X., Dai J. et al. Effective delivery of osteopontin small interference RNA using exosomes suppresses liver fibrosis via TGF-β1 signaling. Front. Pharmacol. 2022; 13: 882243. DOI: 10.3389/fphar.2022.882243

34. Lurie Y., Webb M., Cytter-Kuint R., Shteingart S., Lederkremer G.Z. Non-invasive diagnosis of liver fibrosis and cirrhosis. World J. Gastroenterol. 2015; 21(41): 11567–83. DOI: 10.3748/wjg.v21.i41.11567

35. Li N., Dou Z., Liu J., Chai B., Li Y., An X. et al. Therapeutic Effect of HGF on NASH Mice Through HGF/c-Met and JAK2-STAT3 Signalling Pathway. Ann. Hepatol. 2018; 17(3): 501–10. DOI: 10.5604/01.3001.0011.7395

36. Gharbia S., Nazarie S.R., Dinescu S., Balta C., Herman H., Peteu V.E. et al. Adipose-Derived Stem Cells (ADSCs) Supplemented with Hepatocyte Growth Factor (HGF) Attenuate Hepatic Stellate Cell Activation and Liver Fibrosis by Inhibiting the TGF-β/Smad Signaling Pathway in Chemical-Induced Liver Fibrosis Associated with Diabetes. Cells 2022; 11(21): 3338. DOI: 10.3390/cells11213338

37. Ido A., Moriuchi A., Numata M., Murayama T., Teramukai S., Marusawa H. et al. Safety and pharmacokinetics of recombinant human hepatocyte growth factor (rh-HGF) in patients with fulminant hepatitis: a phase I/II clinical trial, following preclinical studies to ensure safety. J. Transl. Med. 2011; 9: 55. DOI: 10.1186/1479-5876-9-55

38. Márquez-Coello M., Arizcorreta A., Rodríguez-Pardo M., Illanes-Álvarez F., Márquez D., Cuesta-Sancho S. et al. Modifications of liver stiffness and CXCL4, TGF-β1 and HGF are similar in HCV- and HIV/HCV-infected patients after DAAs. Sci. Rep. 2021; 11(1): 9824. DOI: 10.1038/s41598-021-89370-6

39. Narmada B.C., Kang Y., Venkatraman .L, Peng Q., Sakban R.B. et al. Hepatic stellate cell-targeted delivery of hepatocyte growth factor transgene via bile duct infusion enhances its expression at fibrotic foci to regress dimethylnitrosamine-induced liver fibrosis. Hum. Gene Ther. 2013; 24(5): 508–19. DOI: 10.1089/hum.2012.158

40. Porowski D., Wirkowska A., Hryniewiecka E., Wyzgał J., Pacholczyk M., Pączek L. Liver Failure Impairs the Intrahepatic Elimination of Interleukin-6, Tumor Necrosis Factor-Alpha, Hepatocyte Growth Factor, and Transforming Growth Factor-Beta. Biomed. Res. Int. 2015; 2015: 934065. DOI: 10.1155/2015/934065

41. Choi J.S., Jeong I.S., Park Y.J., Kim S.W. HGF and IL-10 expressing ALB::GFP reporter cells generated from iPSCs show robust anti-fibrotic property in acute fibrotic liver model. Stem. Cell Res. Ther. 2020; 11(1): 332. DOI: 10.1186/s13287-020-01745-0

42. Rohn F., Kordes C., Buschmann T., Reichert D., Wammers M., Poschmann G. et al. Impaired integrin α5 /β1 -mediated hepatocyte growth factor release by stellate cells of the aged liver. Aging Cell. 2020; 19(4): e13131. DOI: 10.1111/acel.13131

43. Oe S., Shibata M., Miyagawa K., Honma Y., Hiura M., Abe S. et al. Hepatitis A complicated with acute renal failure and high hepatocyte growth factor: A case report. World J. Gastroenterol. 2015; 21(32): 9671–4. DOI: 10.3748/wjg.v21.i32.9671